Pleuromutilin phosphate compounds, medicinal composition thereof, preparation method thereof and application thereof

A technology of pleuromutilin and phosphate esters, applied in the fields of pharmacology, drug synthesis and pharmacology, can solve the problems of first-pass metabolism and poor water solubility, and achieve the effect of reducing adverse effects and improving water solubility

Inactive Publication Date: 2010-03-17
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI +1
View PDF3 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In order to develop pleuromutilin antibiotics that can be applied to human or animal syst

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pleuromutilin phosphate compounds, medicinal composition thereof, preparation method thereof and application thereof
  • Pleuromutilin phosphate compounds, medicinal composition thereof, preparation method thereof and application thereof
  • Pleuromutilin phosphate compounds, medicinal composition thereof, preparation method thereof and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Example 1: 14-[N-(4-methoxybenzoyl)]-carbamoylmutriptyline-11-dihydrogen phosphate (compound 1)

[0082] (a) Preparation of 14-[N-(4-methoxybenzoyl)]-carbamoylmutriptyline-11-dibenzyl phosphate

[0083]

[0084] Under nitrogen protection, 14-[N-(4-methoxybenzoyl)]-carbamylmutriptyline (200mg, 0.4mmol) and 1-hydrotetrazolium (140mg, 2.0mmol) were dissolved in In 10 mL of dry dichloromethane, stir at room temperature, add dibenzyl N, N'-diisopropyl phosphoramidite (695 mg, 2.0 mmol), continue the reaction for 2 hours, cool to -78 ° C, and add to the reaction A dry dichloromethane solution (5 mL) of m-chloroperoxybenzoic acid (500 mg, 2.0 mmol) was added dropwise to the solution, stirred for 30 minutes, then heated to -20°C and stirred for 1 hour. Slowly add 10% sodium bisulfite aqueous solution (20mL) dropwise to the reaction solution to quench the reaction, add dichloromethane (20mL), separate the layers, and use sodium bisulfite solution, saturated sodium carbonate ...

Embodiment 2

[0088] Example 2 14-[N-(4-methoxybenzoyl)]-carbamoylmutriptyline-11-disodium phosphate (compound 5)

[0089]

[0090] Example 1(b) compound (2g, 3.47mmol) and sodium acetate (0.57g, 6.93mmol) were stirred in water (20mL) until clarified, filtered, and the filtrate was lyophilized to obtain a white solid, which was recrystallized from ethanol and vacuum Drying gave the title compound (1.27 g, 59%). 1 H-NMR (D 2 O, ppm): δ7.96 (d, 2H), 7.15 (d, 2H), 6.43 (dd, 1H), 5.79 (d, 1H), 5.33 (dd, 2H), 4.41 (m, 1H), 3.95 (s,3H), 2.45(q,1H), 0.98-2.6(m,12H), 1.61(s,3H), 1.29(s,3H), 1.14(d,3H), 0.84(d,3H).

Embodiment 314

[0091] Example 314-[N-(4-methoxybenzoyl)]-carbamoyl-19,20-dihydromutriptyline-11-dihydrogen phosphate (compound 2)

[0092]

[0093] Example 1 (a) compound 14-[N-(4-methoxybenzoyl)]-carbamoyl-mutriptyline-11-dibenzyl phosphate (250mg, 0.33mmol) was dissolved in anhydrous methanol (20mL), add 35mg10%Pd / C, shake table catalytic reduction under 3atm hydrogen pressure for 5 hours. 20 / 45μm, the mobile phase was methanol: 0.25% trifluoroacetic acid aqueous solution = 20:80-50:50 gradient elution), and the title product (84.9 mg, 44.5%) was obtained as a white solid powder after lyophilization of the residual aqueous phase. 1 H-NMR (MeOD, ppm): δ7.86 (d, 2H), 7.01 (d, 2H), 5.72 (d, 1H), 4.31 (m, 1H), 3.83 (s, 3H), 2.54 (q, 1H), 0.88-2.4(m, 17H), 1.49(s, 3H), 1.12(s, 3H), 0.86(d, 3H), 0.75(d, 3H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of pharmaceutics, and provides pleuromutilin phosphate compounds shown as a right general formula (I), a medicinal composition thereof, a preparation method thereofand application thereof. The pleuromutilin phosphate compounds have good water solubility, quickly release parent medicaments in vivo after intravenous administration, achieve higher blood concentration, and have excellent anti-infectious activity, so the pleuromutilin phosphate compounds can be used for treating infectious diseases, particularly infectious diseases caused by multi-medicament andmedicament-resistant bacteria.

Description

technical field [0001] The invention belongs to the field of pharmacy and relates to the fields of drug synthesis and pharmacology. More specifically, it relates to a pleuromutilin compound containing a phosphate group, its pharmaceutical composition, its preparation method and its use in the preparation of anti-infective drugs. Background technique [0002] Worldwide emergence of methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE), drug-resistant Streptococcus pneumoniae (PRSP), multidrug-resistant Mycobacterium tuberculosis, and vancomycin-resistant enterococci (VRE) is the most difficult problem in the current clinical anti-infective treatment [Exp. Facing the challenges brought by multidrug-resistant bacteria, it is necessary to develop antibacterial drugs with new mechanisms of action. [0003] Pleuromutilin antibacterial drugs are a class of unique antibacterial drugs isolated from the fermentation broth of fungi Pleurotus mutilus...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07F9/655A61K31/661A61P31/04
CPCC07F9/12C07D451/04C07F9/65182C07F9/6561C07F9/117C07D249/14A61P31/00A61P31/04C07F9/6518
Inventor 杨玉社姜智腾付利强蔡瞻李战晁阳嵇汝运
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap